ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.Journal for immunotherapy of cancer · 2022Trial
- Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study.EClinicalMedicine · 2025Article
- Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.Cell reports. Medicine · 2025Article
- Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.Haematologica · 2025Article
- Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.JCI insight · 2024Article
- Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.Journal for immunotherapy of cancer · 2024Article
- CTLA-4: Checkpoints beyond the membrane.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Fcγ receptors and immunomodulatory antibodies in cancer.Nature reviews. Cancer · 2024Review
- Targeting tumor-infiltrating tregs for improved antitumor responses.Frontiers in immunology · 2024Review
- XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.Journal for immunotherapy of cancer · 2023Article
- Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.Nature cancer · 2022Article
- Finding the Right Heavy Chains for Immunostimulatory Antibodies.International journal of molecular sciences · 2022Review
- Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model.Neoplasia (New York, N.Y.) · 2022Article
- Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.Nature communications · 2022Article
- An anti-CTLA-4 heavy chain-only antibody with enhanced TProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?Cancers · 2022Review
- Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.Frontiers in oncology · 2022Review
- Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.Journal of experimental & clinical cancer research : CR · 2021Review
- Review
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Despite a number of preclinical studies demonstrating that the activity of anti-CTLA-4 antibodies in murine models of cancer relies on effector T-cell activation and regulatory T cell depletion, the activity of the clinical antibodies remains controversial. To decipher such mechanisms is critical to the development of novel and more potent immunotherapies.See related article by Sharma et al., p. 1233.
Indexed as
Identifiers
30291135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.